BRIEF

on NOVACYT (EPA:ALNOV)

Novacyt Publishes Annual Report for 2023

Novacyt S.A., the international molecular diagnostics company, has released its Annual Report and Accounts for the year ending 31 December 2023. The document has been uploaded on the company’s website and will be sent to shareholders holding ordinary shares via CREST Depository Interests (CDIs).

Novacyt, listed on both EURONEXT GROWTH (ALNOV) and AIM (NCYT), offers a broad range of integrated technologies and services in molecular diagnostics. The company aims to provide end-to-end solutions across various sectors, including human health, animal health, and environmental.

For queries, interested parties can contact the corporate team through provided channels. Details and further information are accessible on the Novacyt website.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all NOVACYT news